Assessment of efficacy of a live oral poliovirus vaccine for virulent Sabin-like poliovirus 1 strains in Japan

Acta Virologica

Volumn 50, Issue 2, 2006, Pages 139-143

  Iwai, M ^a   Nakayama, T ^a   Matsuura, K ^a   Hasegawa, S ^a   Ando, S ^a   Obara, M ^a   Nagai, Y ^a   Yoshida, H ^b   Horie, H ^c  

^a TOYAMA INSTITUTE OF HEALTH   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^c OHU UNIVERSITY   (Japan)

Author keywords

Inactivated poliovirus vaccine; Oral poliovirus vaccine; Poliomyelitis; Poliovirus 1; Virulent Sabin like poliovirus

Indexed keywords

NEUTRALIZING ANTIBODY; ORAL POLIOMYELITIS VACCINE; VIRUS ANTIBODY;

ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; HERD IMMUNITY; HUMAN; JAPAN; NONHUMAN; POLIOMYELITIS; POLIOMYELITIS VIRUS 1; VACCINATION; VIRUS STRAIN; WILD TYPE; ADOLESCENT; ADULT; AGED; BLOOD; CHILD; IMMUNOLOGY; INFANT; MIDDLE AGED; POLIOMYELITIS VIRUS; PRESCHOOL CHILD; SERODIAGNOSIS;

HUMAN POLIOVIRUS 1; POLIOVIRUS;

ADOLESCENT; ADULT; AGED; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; JAPAN; MIDDLE AGED; NEUTRALIZATION TESTS; POLIOVIRUS; POLIOVIRUS VACCINE, ORAL;

EID: 33749064983     PISSN: 0001723X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Bellmunt A, May G, Zell R, Pring-Akerblom P, Verhagen W, Heim A (1999): Evolution of poliovirus type 1 during 5.5 years of prolonged enteral replication in an immunodeficient patient. Virology 265, 178-184.
2. Chumakov KM, Powers LB, Noonan KE, Roninson IB, Levenbook IS (1991): Correlation between amount of virus with altered nucleotide sequence and the monkey test for acceptability of oral poliovirus vaccine. Proc. Natl. Acad. Sci. USA 88, 199-203.
3. Chumakov KM, Dragunsky EM, Norwood LP, Douthitt MP, Ran Y, Taffs RE, Ridge J, Levenbook IS (1994): Consistent Selection of Mutations in the 5′-untranslated region of oral poliovirus vaccine upon passaging in vitro. J. Med. Virol. 42, 79-85.
4. Horie H, Yoshida H, Matsuura K, Miyazawa M, Ota Y, Nakayama T, Doi Y, Hashizume S (2002a): Neurovirulence of type 1 polioviruses isolated from sewage in Japan. Appl. Environ. Microbiol. 68, 138-142.
5. Horie H, Yoshida H, Matsuura K, Miyazawa M, Wakabayashi K, Nomoto A, Hashizume S (2002b): Isolation of vaccine-derived type 1 polioviruses displaying similar properties to virulent wild strain Mahoney from sewage in Japan. J. Med. Virol. 68, 445-451.
6. Hovi T, Cantell K, Houvilainen A, Kinnunen E, Kuronen T, Lapinleimu K, Poyry T, Roivainen M, Salama N, Stenvik M, Silander A, Thoden CJ, Salminen S, Weckstrom P (1986): Outbreak of paralytic poliomyelitis in Finland: widespread circulation of antigenically altered poliovirus type 3 in a vaccinated population. Lancet 1, 1427-1432.
7. Infectious Agents Surveillance Center (1997): Poliomyelitis, Japan, 1962-1995. Infect. Agents Surveill. Rep. 18, 1-2.
8. Kew OM, Sutter RW, Nottay BK, McDonough MJ, Prevots DR, Quick L, Pallansch MA (1998): Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient. J. Clin. Microbiol. 36, 2893-2899.
9. Kew OM, Wright P, Agol VI, Delpeyroux F, Shimizu H, Nathanson N, Pallansch MA (2004): Circulating vaccine-derived polioviruses: current state of knowledge. Bull. W.H.O. 82, 16-23.
10. Lago PM, Bravo JR, Andrus JK, Comellas MM, Galindo MA, Quadros CA, Bell E (1994): Lessons from Cuba: mass campaign administration of trivalent oral poliovirus vaccine and seroprevalence of poliovirus neutralizing antibodies. Bull. W.H.O. 72, 221-225.
11. Martin J, Dunn G, Hull R, Patel V, Minor PD (2000): Evolution of the Sabin strain of type 3 poliovirus in an immunodeficient patient during the entire 637-day period of virus excretion. J. Virol. 74, 3001-3010.
12. Matsuura K, Ishikura M, Yoshida H, Nakayama T, Hasegawa S, Ando S, Horie H, Miyamura T, Kitamura T (2000): Assessment of poliovirus eradication in Japan: genomic analysis of the polioviruses isolated from the river water and the sewage in Toyama Prefecture. Appl. Environ. Microbiol. 66, 5087-5091.
13. Ramsay M, Begg N, Gandhi J, Brown D (1994): Antibody response and viral excretion after live polio vaccine or a combined schedule of live and inactivated polio vaccines. Pediatr. Infect. Dis. J. 13, 1117-1121.
14. Recommendation of the Advisory Committee on Immunization Practices (ACIP) (1997): Poliomyelitis prevention in the United States: introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. M.M.W.R. 46 (RR-3), 1-25.
15. Shimojo H (1984): Poliomyelitis Control in Japan. Rev. Infect. Dis. 6 (Suppl. 2), S427-430.
16. Takatsu T, Tagaya I, Hirayama M (1973): Poliomyelitis in Japan during the period 1962-68 after the introduction of mass vaccination with Sabin vaccine. Bull. W.H.O. 49, 129-137.
17. World Health Organization (1995): Manual of laboratory methods for potency testing of vaccines used in the WHO Expanded Programme on Immunization. WHO publication No. WHO/BLG/95.1. World Health Organization, Geneva.
18. World Health Organization Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines (1995): Factors affecting the immunogenicity of oral poliovirus vaccine: a prospective evaluation in Brazil and the Gambia. J. Infect. Dis. 171, 1097-1106.
19. World Health Organization (2003a): Global polio eradication initiative strategic plan 2004-2008. World Health Organization, Geneva.
20. World Health Organization (2003b): Laboratory surveillance for wild and vaccine-derived polioviruses, January 2002-June 2003. Wkly. Epidemiol. Rec. 78, 341-348.
21. Yoshida H, Horie H, Matsuura K, Miyamura T (2000): Characterization of polioviruses isolated from sewage and river water in Japan. Lancet 356, 1461-1463.
22. Yoshida H, Horie H, Matsuura K, Kitamura T, Hashizume S, Miyamura T (2002): Prevalence of vaccine-derived polioviruses in the environment. J. Gen. Virol. 83, 1107-1111.